Smartphone app to examine effects of cannabis use on driving behavior

智能手机应用程序可检查大麻使用对驾驶行为的影响

• 批准号: 10458349
• 负责人: Yingying Chen
• 金额: $ 21.85万
• 依托单位: RUTGERS BIOMEDICAL/HEALTH SCIENCES-RBHS
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-07-01 至 2023-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10458349
• 关键词: Acceleration; Access to Information; Acute; Address; Age; Algorithms; Automobile Driving; Behavior; Biological; Biological Assay; Cannabidiol; Cannabinoids; Cannabis; Cellular Phone; Chronic; Collection; Conscious; Data; Data Collection; Detection; Dose; Drug Kinetics; Ecological momentary assessment; Enrollment; Female; Future; Grain; Hour; Interview; Intoxication; Laws; Life; Liquid substance; Medical Marijuana; Methodology; Methods; Monitor; Oral; Participant; Patient Self-Report; Patients; Pharmaceutical Preparations; Phase; Positioning Attribute; Product Labeling; Public Health; Reaction Time; Reporting; Risk; Route; Saliva; Sampling; Sedation procedure; Smoke; Speed; System; Telephone; Testing; Tetrahydrocannabinol; Time; Vehicle crash; Work; base; cognitive control; deep learning; driving behavior; driving under influence; gender difference; impaired driving performance; improved; innovation; marijuana use; novel; prevent; recruit; saliva sample; sensor; smartphone Application; tool; vaping

ABSTRACT Driving under the influence of cannabis (DUIC) nearly doubles car crash risk, with medical cannabis (MC) patients representing an at-risk group for DUIC. This R21 aims to advance efforts to reduce DUIC through the innovative combination of a smartphone app for objective detection of aberrant driving behaviors, Ecological Momentary Assessment (EMA), and biological sampling (delta-9-tetra-hydrocannabinol: THC; cannabidiol: CBD) to examine effects of cannabis use on driving behavior in real-world conditions among MC patients. This project builds on recent work, which examined both THC and CBD in relation to real-world driving behavior, and addresses limitations of prior work by using EMA to obtain fine-grained data on subjective cannabis effects prior to driving over an extended period (up to 28 days), in addition to collecting a biological sample (THC, CBD) prior to driving for exploratory comparison with EMA report. This R21 also will assess "effort put into driving" (i.e., compensatory effort for cannabis effects) since certain driving behaviors might be modified by "effort" to counteract cannabis effects, whereas other driving behaviors may be less subject to compensatory behaviors. R21 project aims are to: (1) Determine the extent to which THC, based on MC product labeling and self-reported quantity used, are associated with aberrant driving behavior (e.g., sudden braking, weaving) in real life; (2) Examine how EMA report of subjective cannabis intoxication, chronicity of cannabis use, and "effort put into driving" are associated with aberrant driving behavior (e.g., sudden braking) in real life; Exploratory aim: Examine THC and CBD (biological sample prior to driving) as predictors of aberrant driving in real world conditions. To achieve these aims, this R21 will recruit eligible MC patients (N=70, 50% female) for Pilot (n=10) and Study (n=60) phases. In both phases, participants complete a baseline lab assessment, followed by daily data collection (EMA; phone sensor data collection for objective detection of driving behavior with high accuracy: >96%), collection of a biological sample prior to driving (concurrent with EMA report prior to driving) for one week, and a final post-data collection lab assessment and qualitative interview. Study Phase will use qualitative data to refine the app and identify new app features to be added to prevent DUIC in future work. Analyses will explore gender differences. The innovative use of a smartphone app for objective detection of aberrant driving behavior, combined with EMA and biological sampling (THC, CBD), will provide important, new findings on effects (subjective and objective) of cannabis (THC, CBD) and compensatory "effort" on driving behavior in daily life in MC patients to enable urgently needed advances to reduce DUIC.

抽象的 在大麻（DUIC）的影响下驾驶几乎使车祸风险增加了一倍，医用大麻（MC） 代表DUIC风险组的患者。该R21旨在促进通过减少DUIC的努力 智能手机应用程序的创新组合，用于客观检测异常驾驶行为，生态学 瞬时评估（EMA）和生物学采样（Delta-9-tetra-Hydrocanbinol：THC；大麻二酚： CBD）检查MC患者在现实情况下使用大麻对驾驶行为的影响。这 项目基于最近的工作，该工作研究了与现实世界驾驶行为有关的THC和CBD， 并通过使用EMA获得有关主观大麻效应的细粒度数据来解决先前工作的局限性 除了收集生物样品（THC， CBD）在开车与EMA报告进行探索性比较之前。此R21还将评估“付出的努力 驾驶”（即大麻效应的补偿努力），因为某些驾驶行为可能会通过 “努力”来抵消大麻效应，而其他驾驶行为可能较少受到补偿性 行为。 R21项目的目的是：（1）确定基于MC产品标签的THC的程度 自我报告的数量与异常驾驶行为（例如，突然制动，编织）有关 现实生活； （2）检查EMA主观大麻中毒，大麻使用的慢性和 “驾驶努力”与现实生活中的异常驾驶行为（例如突然制动）有关； 探索目的：检查THC和CBD（驾驶前的生物样品）作为异常驾驶的预测指标 现实世界条件。为了实现这些目标，该R21将招募合格的MC患者（n = 70，50％女性） 飞行员（n = 10）和研究（n = 60）阶段。在这两个阶段，参与者都完成了基线实验室评估， 其次是每日数据收集（EMA；电话传感器数据收集，用于客观检测驾驶行为 具有高精度：> 96％），在驾驶之前收集生物样品（与EMA报告之前 驾驶）一周，以及最终的DATA集合实验室评估和定性访谈。研究阶段 将使用定性数据来完善应用程序并确定以后添加以防止DUIC的新应用功能 工作。分析将探索性别差异。智能手机应用程序的创新使用用于客观检测 异常的驾驶行为，结合EMA和生物采样（THC，CBD），将提供重要的， 关于大麻（THC，CBD）效果（主观和客观）的新发现和补偿性的“努力” MC患者日常生活中的行为，使迫切需要进步以减少DUIC。